FDA expands pediatric use of Bristol's HIV drug Sustiva

05/6/2013 | Drug Store News · RTT News

The FDA approved Bristol-Myers Squibb's Sustiva, or efavirenz, to treat HIV-1 patients ages 3 months to 3 years who weigh at least 7.7 pounds. The approval covers sprinkle administration when swallowing a capsule or tablet isn't possible. The drug was evaluated in three open-label trials involving 182 patients.

View Full Article in:

Drug Store News · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Principal Engineer - Service (US/MI/00/0043/SL) - 14000009CP
Abbott
Chicago, IL
Senior Manager, Compliance
Stryker
Fremont, CA
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA